Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex

Resolution of Neuromuscular Blockade Clinical Trial

Official title:

Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02401841
• Other study ID #: Policlinico 12
• Status: Recruiting
• Phase: N/A
• First received: March 18, 2015
• Last updated: October 19, 2015
• Start date: January 2015

Study information

• Verified date: October 2015
• Source: Policlinico Hospital
• Contact: Davide Chiumello, MD
• Email: chiumello[@]libero.it
• Is FDA regulated: No
• Health authority: Comitato etico area B Milano: Italy
• Study type: Observational

Clinical Trial Summary

It is a observational prospective study. The aim of this study is to compare neostigmine vs sugammadex in the resolution of neuro-muscular blockade in great obese patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Great obese

• Videolaparoscopic surgery

Exclusion Criteria:

• Age under 18

• No acceptation of informed consent

• New York Heart Association > 2

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Resolution of Neuromuscular Blockade

Intervention

Drug:
• Two different types of drug for resolution of neuro-muscular blockade

Locations

Country	Name	City	State
Italy	Fondazione IRCC Ca' Granda - Ospedale Maggiore Policlinico	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Policlinico Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in neuro-muscular block resolution time between two groups		up to 36 months	Yes